Affimed NV (NAS:AFMD)
$ 5.24 -0.02 (-0.38%) Market Cap: 79.79 Mil Enterprise Value: 22.43 Mil PE Ratio: 0 PB Ratio: 1.25 GF Score: 54/100

Affimed N.V. - Special Call Transcript

Mar 10, 2021 / 01:30PM GMT
Release Date Price: $67.7 (+23.77%)
Operator

Good day, ladies and gentlemen, and thank you for standing by. I would like to welcome you to today's conference call by Affimed to discuss the results of its REDIRECT trial interim analysis. The call today includes the presentation, followed by a question-and-answer session. (Operator Instructions) As a reminder, today's conference call is being recorded.

I would now like to introduce your host for today's call, Alex Fudukidis, Head of Investor Relations at Affimed. Please go ahead, sir.

Alexander Fudukidis
Affimed N.V. - Head of IR

Thank you, Leanne. I'd like to welcome and thank you all for joining us today to discuss the interim analysis of AFM13-202, our REDIRECT study that investigate AFM13 monotherapy in the treatment of peripheral T cell lymphoma patients.

The press release announcing the continuation of the REDIRECT study and the outcome of the preplanned interim futility analysis was issued earlier today and can be found on the Investor Relations section of our website. We have also posted slides that will be used to guide our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot